Advertisement
Advertisement

IART

IART logo

Integra LifeSciences Holdings

12.41
USD
Sponsored
-0.27
-2.09%
Dec 31, 15:59 UTC -5
Closed
exchange

After-Market

12.45

+0.04
+0.28%

IART Earnings Reports

Positive Surprise Ratio

IART beat 23 of 40 last estimates.

57%

Next Report

Date of Next Report
Feb 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
$438.21M
/
$0.81
Implied change from Q3 25 (Revenue/ EPS)
+8.99%
/
+50.00%
Implied change from Q4 24 (Revenue/ EPS)
-1.00%
/
-16.49%

Integra LifeSciences Holdings earnings per share and revenue

On Oct 30, 2025, IART reported earnings of 0.54 USD per share (EPS) for Q3 25, beating the estimate of 0.44 USD, resulting in a 21.70% surprise. Revenue reached 402.06 million, compared to an expected 422.54 million, with a -4.85% difference. The market reacted with a -23.46% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of 0.81 USD, with revenue projected to reach 438.21 million USD, implying an increase of 50.00% EPS, and increase of 8.99% in Revenue from the last quarter.
FAQ
For Q3 2025, Integra LifeSciences Holdings reported EPS of $0.54, beating estimates by 21.7%, and revenue of $402.06M, -4.85% below expectations.
The stock price moved down -23.46%, changed from $15.43 before the earnings release to $11.81 the day after.
The next earning report is scheduled for Feb 23, 2026.
Based on 12 analysts, Integra LifeSciences Holdings is expected to report EPS of $0.81 and revenue of $438.21M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement